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Abstract  
Background & Aims: To improve outcomes of two-staged hepatectomies for large/multiple liver 
tumors, portal vein ligation (PVL) has been combined with parenchymal transection (coined ALPPS; 
Associated Liver Partition and Portal vein ligation for Staged hepatectomy) to greatly accelerate liver 
regeneration. In a novel ALPPS mouse model, we have reported paracrine Indian hedgehog (IHH) 
signaling from stellate cells as an early contributor to augmented regeneration. Here, we sought to 
identify upstream regulators of IHH.  
Methods: ALPPS in mice was compared against PVL and additional control surgeries. Potential IHH 
regulators were identified through in silico mining of transcriptomic data. JNK1 activity was reduced 
through SP600125 to evaluate its effects on IHH signaling. Recombinant IHH was injected after JNK 
diminution to substantiate their relationship during accelerated liver regeneration. 
Results: Mining linked Ihh to Mapk8. JNK1 upregulation after ALPPS was validated and preceded the 
IHH peak. On immunofluorescence, JNK1 and IHH co-localized in ASMA-positive non-parenchymal 
cells. Inhibition of JNK1 prior to ALPPS surgery reduced liver weight gain to PVL levels and was 
accompanied by downregulation of hepatocellular proliferation and the IHH-GLI1-CCND1 axis. In 
JNK1-inhibited mice, recombinant IHH restored ALPPS-like acceleration of regeneration and re-
elevated JNK1 activity, suggesting the presence of a positive IHH-JNK1 feedback loop.  
Conclusions: JNK1-mediated induction of IHH paracrine signaling from HSCs is essential for 
accelerated regeneration of parenchymal mass. The JNK1-IHH axis is a mechanism unique to ALPPS 
surgery and may point to therapeutic alternatives for patients with insufficient regenerative capacity.   
Lay Summary: ALPPS, a novel two-staged hepatectomy, induces an unprecedented acceleration of 
liver regeneration to enable treatment of unresectable liver tumors. Here, we demonstrate JNK1-IHH 
signaling as a mechanism underlying the regenerative acceleration induced by ALPPS.  
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Introduction 
The unique ability of mammalian liver to regain mass after tissue loss has revolutionized the 
treatment and cure of many patients with liver tumors. However, there are limitations to effective 
regeneration, as hepatic failure may develop after extensive liver resection. This entity, known as the 
small-for-size syndrome (SFSS), results from an insufficient functional volume of the liver remnant 
and remains the most frequent cause of death due to liver surgery.1, 2 Two-staged hepatectomies were 
introduced to reduce the SFSS risk. Typically, the portal vein draining the part of the liver containing 
the tumor is occluded (step 1), causing growth of the contralateral liver part (defined as the future 
remnant liver (FRL)); when the FRL has gained sufficient functional volume, step 2 (resection of the 
diseased part) is performed.2, 3 Nevertheless, in some cases regeneration is still insufficient, or the 
considerable time period between step 1 and 2 allows for further progression of the disease.4, 5 To 
additionally reduce the risk of SFSS in patients with large or multiple liver tumors, ALPPS 
(Associated Liver Partition and Portal vein ligation for Staged hepatectomy: the combination of portal 
vein ligation with parenchymal transection) has been showcased as a procedure that induces 
accelerated liver regeneration and greatly reduces the interval between steps, allowing treatment of 
patients otherwise deemed as unresectable.6, 7 This procedure, introduced about five years ago, has 
gained sustained acceptance with more than 1000 cases included in an international registry 
(http://www.alpps.net/?q=registry).  
 Although there have been several clinical studies evaluating ALPPS in patients, reports on the 
molecular mechanisms underlying the regenerative acceleration following ALPPS-step 1 remain 
scarce. Several components known to be necessary for liver regeneration after partial hepatectomy 
have likewise been associated with accelerated regeneration. In rodent models, IL-6 and TNFα - 
established mediators of liver regeneration - have been found upregulated in ALPPS at the mRNA and 
protein level. Similarly, protein expression of STAT3, RELA, and YAP1 – known transcription 
factors in the regenerating liver - were elevated after ALPPS step 1.8, 9 Furthermore, hypoxia has 
recently been shown to be an important driver of normal regeneration through HIF2α, with 
preliminary studies pointing to the importance of hypoxia also in ALPPS.10, 11 In human ALPPS 
4 
 
tissues, IL-6 and TNFα have been validated on the mRNA level.12 However, none of these molecules 
seems to be unique to the ALPPS-induced acceleration of regeneration.  
We have developed a mouse model of ALPPS and documented the release of serum factors 
that can accelerate regeneration in mice following portal vein ligation (PVL) only to levels seen after 
the complete ALPPS-step 1 procedure.12 These findings suggest that humoral factors must play 
essential roles in the early instigation of accelerated regeneration. With this mouse model, we 
established that the secretion of Indian Hedgehog (IHH) from hepatic stellate cells (HSCs) was 
necessary for the early activation and progression of accelerated regeneration.13 Although hedgehog 
signaling has previously been reported to be required for regeneration after hepatectomy, the early 
elevations in serum IHH were unique to ALPPS, and not observed following hepatectomy or other 
surgeries.13  
Hedgehog activity is barely detectable in healthy adult liver. Upon hepatectomy, however, 
hepatocytes begin to proliferate and HSCs undergo differentiation into myofibroblastic and fibrogenic 
states.14, 15 Furthermore, there is increasing evidence that morphogenic signals - such as the hedgehog 
pathway - are mediators of the myofibroblastic HSC switch. When blocking or knocking out Smo, the 
receptor for hedgehog ligands, HSCs do not acquire myofibroblastic traits, and subsequent hepatocyte 
regeneration is inhibited.16, 17, 18  
Given the specific secretion of IHH after ALPPS, this study sought to identify upstream 
regulators of the ligand as to establish the role of IHH in ALPPS. On the other hand, expanding on the 
networks that act to accelerate regeneration after ALPPS may provide insight into new therapeutics for 
the pharmacological promotion of regeneration in clinical settings.   
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Materials and Methods  
Animals  
All animal experiments were performed in accordance with Swiss Federal Animal Regulations 
and approved by the Veterinary Office of Zurich. Male C57Bl/6 mice (Envigo, Horst, NL) aged 10-12 
weeks kept on a 12-hour day/night cycle with free access to food and water were used.  
Animal surgery and treatment 
To mimic human ALPPS surgery in mice, 90% PVL was performed leaving a 10% functional 
remnant consisting of the left and a part of the right middle lobe. Then, a partial 80% transection was 
done through the middle lobe along the demarcation line of the occluded/non-occluded parenchyme. 
The left lateral lobe (LLL, 25% of liver volume) was also resected to simulate the cleaning of the liver 
from smaller tumors as often done in human ALPPS. Details on isoflurane anesthesia, buprenorphine 
analgesia, ALPPS procedures, and the control operations (90% PVL, 80% transection, and sham 
laparotomy) have been described.12, 13 After surgery, animals were allowed to recover on a warming 
pad in a separate cage until completely conscious. Animals were weighed before surgery and at 
sacrifice, where weight of resected and remnant liver was recorded. Tissue was formalin fixed or snap 
frozen, while plasma was stored at -80°C for analysis.  
SP600125 (0.016mg/gram BW, InVivoGen, tlrl-sp60 Toulouse, FR), a specific JNK inhibitor, or 
DMSO in oil was injected I.P. one hour before operation. Recombinant Ihh (200 ng/kg, 160µl final 
volume; R&D, 1705-HH-025/CF Minneapolis, MN) or PBS was injected into the vena cava right after 
operation. Ihh antibody (4ug/kg, 160µl final volume; R&D MAB8048) or PBS was injected via tail 
vein one hour before operation.  
Liver regeneration  
Liver regeneration was assessed by the percentage of functional-liver-remnant-to-body weight 
ratio (FLR/BW) derived from six animals per group and time point.  
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In-silico analysis 
RNA sequencing raw data of the accession number PRJEB15593 in the European Nucleotide 
Archive (ENA) was used for in-silico analysis via the online String Database (string-db.org). 
Protein analysis 
Western blotting was performed as described.19 Antibodies are listed in Supplementary Table 2. 
NE-PER Nuclear and Cytoplasmic Extraction reagents (Thermo Fisher Scientific, Waltham, MA, 
PK207589) were used to isolate subcellular fractions, with their separation ascertained through β-
tubulin (cytoplasmic) and lamin B1 (nuclear) blotting. IHH protein levels were measured by ELISA 
(mouse IHH: Cusabio, CSB-E16517m). Immunoblots are provided in Supplementary File 
Immunoblots. 
Statistical Analysis.  
Data are expressed as mean ±SD. Differences between groups (n=6/group unless for expression 
profiling with n=3/group and for histological counting with n=5/group) were determined using 
unpaired, two-tailed t tests assuming unequal variance via GraphPad Prism v4.0 (GraphPad, San 
Diego CA), with significance set at P<0.05. Analyses were performed in a blinded way.   
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Results 
Early upregulation of JNK1 in accelerated liver regeneration 
To identify potential upstream regulators of the IHH pathway in accelerated liver regeneration 
we conducted an in-silico analysis of our RNA sequencing data sets derived from livers at early times 
after ALPPS, PVL, transection, or sham surgery.13 Genes that discriminated ALPPS liver from other 
surgeries were included. Using string.db.org, Mapk8 was text-mined to be linked to Ihh and Ccnd1 of 
the hedgehog pathway (Fig 1A). Our RNA seq data suggested Mapk8 upregulation at early times after 
ALPPS, which we confirmed by qPCR in a new set of animals subjected to the different surgeries 
(Figure 1B). The deregulation of JNK1 was further confirmed on the protein level. pJNK1, the active 
form of JNK phosphorylated on Thr183 and Tyr185, was upregulated as early as 1 hour after ALPPS 
(Fig 1C). Therefore, JNK1 activation through ALPPS surgery precedes the serum IHH peak that we 
have previously observed at 4h post operation.13 From these findings, we hypothesized that JNK1 
plays a part in accelerated liver regeneration as a potential instigator of IHH signaling.  
 
Ihh and JNK1 are present in activated non-parenchymal cells  
 To establish an association between JNK1 and IHH signaling, we stained liver sections 4h 
after  operation (ALPPS, PVL, transection, and sham) for IHH, ASMA (a marker of activated hepatic 
stellate cells), 20, 21 and pJNK1. Non-parenchymal cells were positive for all the three proteins across 
samples (Supplementary Fig 1), suggesting pJNK1 and IHH may interact in stellate cells to accelerate 
regeneration. To assess localization of IHH and pJNK1 in activated hepatic stellate cells, we applied 
immunofluorescence (Fig 2A, Supplementary Fig 2) to paraffin-embedded liver sections after 
operation. pJNK1 co-localized with both αSMA and IHH, indicating their simultaneous presence in 
activated stellate cells.  
 JNK1 is thought to preferentially act in nuclei when phosphorylated.22, 23 To substantiate an 
JNK-IHH association, we prepared cytosolic and nuclear fractions from liver at 4h and 24h post 
surgery and assessed protein levels of pJNK1, the IHH downstream effector and transcription factor 
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GLI1, and its proliferative target CCND1.13 Indeed, the nuclear increases in pJNK were paralleled by 
increases in GLI1, while nuclear levels of total JNK1 and GLI2 remained unchanged (Supplementary 
Fig 3). CCND1 was significantly elevated at 24h in nuclear fractions (Figure 2C), fitting its delayed 
induction seen on immunoblots 8h after ALPPS as previously reported.13 On the other hand, a non-
significant elevation in CCND1-positive hepatocyte nuclei was noted on immunohistochemistry at 4h 
post ALPPS, and was accompanied with increases in proliferative marker (Ki67, pH3) counts. 
Likewise, the elevated nuclear CCND1 positivity correlated with Ki67/pH3 increases at 24h post 
ALPPS (Figure 2C, Supplementary Fig 4).  
 These findings associate JNK1 activation with both the induction of IHH signaling and the 
promotion of proliferation following ALPPS. Therefore, JNK1 may foster regeneration in ALPPS by 
causing release of IHH from stellate cells to induce paracrine proliferation of hepatocytes via GLI1-
CCND1.13, 22, 24, 25, 26 
 
Reduction of JNK1 activity in ALPPS-treated mice abolishes regenerative acceleration  
 If the elevated activity of JNK1 after ALPPS is promoting acceleration of regeneration, 
inhibiting JNK should reduce the ALPPS effects. To decrease JNK1 activity, we chose SP600125, a 
specific JNK inhibitor that has been widely used in liver regeneration studies due to its specificity and 
ease of application.27, 28 SP600125 was injected 1h prior to ALPPS surgery, and the assessment of 
pJNK1 levels in nuclear fractions confirmed a partial inhibition of the protein, with pJNK1 declining 
to levels seen in mice 4h after PVL (Fig 3A, Supplementary Fig 5).  
 DMSO vehicle injections had no significant impact on body and liver weight after ALPPS, 
although DMSO seemed to reduce the ALPPS effects slightly. In contrast, SP600125 significantly 
reduced the FLR/BW down to levels seen after PVL (Figure 3B). Congruent changes were observed 
for the proliferative markers Ki67 and pH3 in SP600125-treated animals (Figure 3C, Supplementary 
Figure 6). We conclude that partial JNK inhibition prior to ALPPS surgery reduces the regenerative 
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speed to levels comparable to those after PVL. Therefore, JNK1 is an important instigator of the 
ALPPS-specific acceleration of liver regeneration.  
The inhibition of JNK1 downregulates the IHH-GLI1-CCND1 axis in hedgehog signaling 
 To determine whether JNK1 may act through IHH signaling, we assessed the IHH pathway 
components in ALPPS mice treated with SP6100125 or control DMSO injection.  
 Following ALPPS, IHH protein levels peak in serum at 4h with little changes in the liver, 
consistent with the secretion of the ligand from stellate cells. The increases in serum IHH then promote 
GLI1 nuclear translocation, downregulation of the hedgehog inhibitor HHIP, and CCND1 upregulation 
from 4h onwards after ALPPS.13 Treatment with SP600125 reduced both serum and hepatic levels of 
IHH 4h post ALPPS (Figure 4A), suggesting JNK1 inhibits production and/or release of the hedgehog 
ligand. Consistent with IHH downregulation, Gli1 expression was decreased at 4h and 24h (Figure 4B), 
while Hhip expression was increased by SP600125 treatment at 4h after ALPPS (Figure 4C). Likewise, 
GLI1 protein and its target CCND1 were downregulated in nuclear fractions of ALPPS liver at 4h and 
24h compared to vehicle controls (Figure 4C). Immunohistochemistry confirmed the reductions in 
nuclear GLI1 and CCND1 (Figure 4E-F, Supplementary Figure 9) with SP600125 treatment. No 
significant expression changes were observed for Ptch1, Smo, Gli2 (Supplementary Figure 7) and 
nuclear GLI2 (Supplementary Figure 8), all molecules the expression of which does not change 
following IHH stimulation in ALPPS.13 These findings identify IHH signaling as a potential mediator 
of JNK1's ability to accelerate regeneration in ALPPS.  
 
Recombinant IHH rescues ALPPS-induced regeneration after JNK inhibition  
 If JNK1 is promoting its accelerating effects through IHH signaling, restoring IHH levels in 
SP600125-treated liver should re-accelerate the regenerative response after ALPPS surgery.  
 Mice were pretreated with SP600125, ALPPS-operated, injected with recombinant ligand 
(rIHH), and compared to vehicle (DMSO & PBS)-treated ALPPS controls. When assessing body weight 
after all treatments, no differences were observed between the groups. In contrast, the FLR/BW was 
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significantly elevated after ALPPS+SP6+rIHH compared to ALPPS+SP6 (Figure 5A). Notably, 
DMSO/PBS injection on its own seemed to have some negative impact on ALPPS-regeneration. 
Nonetheless, liver weight was statistically similar for the ALPPS+DMSO+PBS and the 
ALPPS+SP6+rIHH groups (Figure 5A). Likewise, congruent changes were observed for the 
proliferative markers Ki67 and pH3 (Figure 5B, Supplementary Figure 10). Therefore, rIHH can 
compensate for the inhibition of JNK1 during ALPPS-associated regeneration.  
 
Recombinant IHH re-instates hedgehog signaling and promotes JNK1 activity in SP600125-treated 
ALPPS liver  
 To further elucidate the relationship between JNK1 and IHH in ALPPS, we evaluated the levels 
of the individual pathway components. In SP600125-ALPPS-treated mice, rIHH increased Gli1 and 
decreased Hhip expression (Figure 6A), as well as promoted nuclear GLI1 and CCND1 on immunoblots 
and immunochemistry (Figure 6B-D, Supplementary Figure 11). Again, Ptch, Smo, Gli2 
(Supplementary Figure 12), and GLI2 (Supplementary Figure 13) were not significantly affected. 
Intriguingly, when assessing JNK1, rIHH also increased the levels of nuclear JNK1 (Supplementary 
Figure 14) and of nuclear pJNK1 on both immunoblots (Figure 6E) and immunohistochemistry 
(Supplementary Figure 15). Therefore, IHH can increase the activity of JNK1 in ALPPS liver with 
partially inhibited JNK1, suggesting the presence of a positive feedback loop between JNK1 and IHH. 
Altogether, these findings establish IHH as a downstream effector of JNK1 in the acceleration of 
regeneration after ALPPS surgery.   
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Discussion 
Liver regeneration is a complex molecular response unique in its ability to restore full function 
to the organ.29 Many pathways have been identified to participate, such as signaling through the 
hedgehog pathway.18,28 Nevertheless, liver regeneration does not occur in all patient scenarios, as liver 
failure ensues if the loss of functional tissue is too extensive.4 With the introduction of ALPPS, the 
regenerative capacity has been extended and is expected to improve outcomes of two-staged 
hepatectomies in patients with marginal qualifications for resection. The unprecedented effect of 
ALPPS on liver recovery has provoked strong interest in the mechanisms underlying the acceleration 
of liver regeneration.   
Here, we demonstrate a hitherto undescribed interaction between JNK1 and IHH in stellate 
cells that acts to instigate accelerated liver regeneration early after ALPPS step 1 surgery. More 
specifically, we demonstrate that (i) JNK1 activation is associated with liver weight gain and precedes 
the upregulation of IHH-GLI1-CCND1 signaling, (ii) partial inhibition of JNK1 reduces the rate of 
regeneration to that seen after PVL alone, along with congruent decreases in the IHH-GLI1-CCND1 
axis, and that (iii) recombinant IHH is sufficient to restore ALPPS regeneration in JNK1-inhibited 
mice.  
The alterations we observed following ALPPS, SP600125, and rIHH treatments were 
consistently reflected in GLI1-CCND1 nuclear levels and were strongly correlated with changes in 
proliferative markers as well as liver weight changes. On the other hand, molecules of the hedgehog 
pathway that were not affected through IHH (i.e. Ptch, Smo, GLI2) were also not altered through 
JNK1 manipulation. Moreover, the changes in these hedgehog components were examined via PCR, 
Western blots as well as immunohistochemical approaches. Therefore, we can reliably conclude that 
JNK1 initiates the IHH-GLI1-CCND1 axis in accelerated regeneration.  
As a limitation to this study, pharmaceutical inhibition was employed to inhibit JNK1 activity 
during our ALPPS experiments. Genetic knockout models may provide more clear-cut evidence; 
however, we decided for a pharmacological approach to reduce rather than block JNK activity, given 
the presence of low levels of pJNK1 also after PVL, the main ALPPS control surgery. Knockdown 
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strategies may be an alternative, however SP600125 has been widely used in liver research including 
regeneration studies, 22, 23, 26, 28, 32 rendering our study comparable to existing work on hepatic JNK.  
JNK1’s role after partial hepatectomy has been revealed by the observation that its inhibition 
blocks hepatocyte proliferation and liver regeneration.18, 28, 30 JNK1 is activated within one hour after 
partial hepatectomy, leading to AP-1 activation, the promotion of cyclin D1 expression, and 
hepatocellular G0-G1 transition.22, 30, 31 Interestingly, through studies in fibrosis, JNK1 was found to be 
involved in HSC activation, where it promotes ASMA expression and HSC proliferation.22, 32 The 
morphogenic hedgehog network likewise is recognized to be essential to liver regeneration and to 
promote expansion of activated HSCs.13, 15, 18, 33 However, whether JNK1 interacts with the Hedgehog 
pathway after partial hepatectomy is unknown. 
In analogy to regeneration after partial hepatectomy, we observed JNK1 upregulation one hour 
after ALPPS. Furthermore, JNK1 localized to activated HSCs. The co-localization of IHH and JNK1 
in activated HSCs suggested a novel link between these two molecules, which we could demonstrate 
through SP600125 and recombinant IHH. Indeed, studies in skin cancer have revealed a link between 
JNK1 and the hedgehog pathway; there, JUN (the canonical JNK1 target) required synergistic 
interaction with GLI1 for full activation of downstream molecules.34 Therefore, complex interactions 
appear to exist between JNK1 and hedgehog signaling.   
Unlike after partial hepatectomy, ALPPS did not increase the number of ASMA-positive cells, 
suggesting JNK1 activity does not promote HSC activation in these settings. While JNK1 clearly 
promotes regeneration after hepatectomy and ALPPS, the associated mechanisms seem to differ in 
some aspects. In ALPPS, the interaction between JNK1 and IHH is key in instigating accelerated 
regeneration. The extent to which IHH participates in regeneration after hepatectomy is unknown; 
however, the early, strong IHH secretion is unique after ALPPS, as plasma IHH increases occur at 
much later times and only at modest levels after resection.13, 18 On the other hand, we observed a 
statistically significant elevation of serum SHH at 4h after partial hepatectomy relative to ALPPS [13], 
suggesting SHH rather than IHH may be the hedgehog ligand relevant after resection. However, 
whether JNK1 is interacting with SHH after hepatectomy remains unknown. In mice, hepatectomy 
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leads to little parenchymal injury, whereas in ALPPS, liver injury through parenchymal transection is 
preceded by ligation, which on its own induces regeneration through mechanisms that are ill-defined. 
Therefore, the divergent nature of the initial regenerative stimuli may underlie the timing and the set of 
interacting proteins/pathways that define the speed of regeneration after a given surgery.  
In this regard, an intriguing observation is that recombinant IHH not only restored accelerated 
regeneration in SP600125-treated mice, but in parallel increased the activity of the partially inhibited 
JNK1. These findings imply IHH enhances JNK1 activities in retrograde to promote its own secretion. 
While further evidence is required to establish such mechanisms, a positive feedback loop between 
JNK1 and IHH would provide an attractive explanation for the enhanced IHH secretion and the 
regenerative acceleration unique to ALPPS.  
Interestingly, both JNK and Hedgehog have prominent roles in the handling of liver injury. 
JNK is most notably activated by TNF-alpha, a cytokine involved in the pathophysiology of many 
types of liver injury, including viral hepatitis, alcoholic liver disease, and ischemia-reperfusion injury. 
Activated JNK phosphorylates its targets (c-Jun, ATF-2, and JunD), and these transcription factors 
then activate genes that are involved in the regulation of inflammation, proliferation, and cell death. In 
the past few years, the use of JNK inhibitors has led to the understanding that the duration of JNK 
activation is critical for its pro-apoptotic effects in injury.35 For example, Gunawan et al showed that 
transient blockade of JNK activity through SP600125 was able to rescue mice from acetaminophen-
induced liver injury.36 Similarly, the Hedgehog pathway has been identified to play a role in liver 
repair such as in regeneration and acute liver injury. In fibrogenic repair, production of Hedgehog 
ligands increases to permit ligand-receptor interaction and activation of the Hedgehog signaling 
pathway, which is thought to be vital for the reconstitution of normal liver architecture.37 In other 
tissues such as skin, reduced SHH production has been associated with the delayed healing seen in 
mice with diabetes, a condition closely related to liver disease.38 Therefore, transient activation of JNK 
and Hedgehog pathways are important physiological processes fostering the repair of injured liver 
tissue. 
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Chronic activation of JNK1, however, has been associated with the development and 
progression of hepatocellular carcinoma (HCC).39 Consistent JNK1 activity has been reported to 
predict a bad outcome in HCC, an aspect that perhaps relates to JNK1 activation secondary to chronic 
liver injury, an accepted cause of HCC. Although the pro-apoptotic function of JNK1 has been related 
to anti-cancerous actions,40 recent evidence indicates a more complex situation, as JNK1 may directly 
promote the repair of DNA breaks.39 These observations suggest a disturbed balance between the 
removal or repair of damaged hepatocytes that underlies JNK1's association with a bad HCC 
outcome.39 Indeed, a dual role of JNK1 in HCC has been postulated through animal models, where 
either its loss or its overactivation contribute to the development of malignancy.22 Similarly, chronic 
hedgehog signaling has been linked to HCC. High levels of hedgehog components in HCC seem to 
maintain the proliferation of cancer stem cells, thereby contributing to HCC progression.41 Likewise, 
liver diseases associated with chronic injury and an elevated HCC risk (i.e. nonalcoholic fatty liver 
disease) are accompanied by a chronic overactivation of the hedgehog pathway.42 On the other hand, 
JNK1 and hedgehog activities remain associated with the successful healing of tissue injury, consistent 
with the view that transient activity of these molecules may be beneficial for the liver.16, 18, 28, 31, 38, 43 
The first cases of ALPPS occurred in patients in Germany where the technique to induce 
accelerated regeneration of the liver was discovered by chance.6, 7 By combination of portal vein 
ligation and transection, extensive tumor resection was performed and patient recovery occurred in 
record time.44, 45, 46 The understanding of ALPPS-triggered processes is in its infancy; however, 
underlying mechanisms begin to emerge, with the JNK1-IHH axis a first example of ALPPS-specific 
molecular events that can be associated with the unprecedented regenerative acceleration. Short-term 
activation of JNK1 and IHH might be of use in the clinic. Not every patient requiring ALPPS may 
qualify for this major surgery; for example, highly morbid patients that may tolerate PVL, but not the 
more invasive ALPPS, may benefit from a JNK1-IHH-based promotion of regeneration. Although the 
oncological risks associated with long-term activation will not vanish, the prevention of imminent 
death due to liver failure may justify the use of compounds activating the JNK1-IHH pathway. 
Understanding the extent to which the JNK1 and IHH signals can be stimulated may open the 
15 
 
opportunity for pharmacological administration to encourage regeneration in at-risk-patients, 
eventually expanding the boundaries of success in the treatment of liver disease one step further.  
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Figure Legends 
Figure 1. JNK1 is upregulated early after ALPPS. (A) In-silico analysis linking components of the 
hedgehog pathways to Mapk8 (JNK1) by the String database.  Green lines represent suspected links 
between genes from their database of publications. Blue and pink lines represent experimentally 
determined links between genes. (B) Raw hepatic gene expression values of Mapk8 from RNA 
sequencing data and corresponding qPCR validation.  (C) Hepatic protein expression (normalized to 
GAPDH) of JNK1 and pJNK1 after surgery. N=5/group, t-test, *P<0.05, ** P<0.01. ***P<0.001. 
Significances refer to ALPPS vs. PVL comparison. 
 
Figure 2. JNK1/IHH cellular location and associated downstream signaling in liver (A) pJNK1/alpha-
SMA and pJNK1/Ihh immunofluorescence co-stain showing co-localization of both proteins in 
nonparenchymal cells (see Supplementary Figure 1 and 2 for stainings in control surgeries) . (B) 
Cytosolic and nuclear protein levels (normalized to β-tubulin and lamin B1, respectively; see 
immunoblots in Supplementary Figure 16) of pJNK1, GLI1, and Cyclin D. (C)  Counts of cyclin D, 
Ki67, and bold pH3-positive hepatocyte nuclei hepatocyte counts(see Supplementary Figure 4 for 
corresponding stains). . N=5/group. t-test, *P<0.05,** P<0.01, ***P<0.001. Significances refer to 
ALPPS vs. PVL comparison. 
 
Figure 3. JNK1 inhibition reduces the regenerative speed after ALPPS. (A) Cytosolic and nuclear 
pJNK1 levels (normalized to β-tubulin and lamin B1, respectively; see Supplementary Fig. 16 for 
immunoblots in). N=5/group. (B) Body weight and liver weight regain (expressed as percent FLR/BW) 
after surgery and treatment with SP600125 are shown in the left and right graph, respectively. (C) 
Corresponding Ki67 and pH3 counts (see Supplementary Fig. 6 for stains). N=5/group, t-test, *P<0.05, 
**P<0.01, ***P<0.001 for ALPPS + DMSO versus ALPPS + SP6 unless otherwise indicated.  
 
Figure 4. JNK1 inhibition dpwnregulates the IHH pathway after ALPPS. (A) Plasma IHH levels 
(ELISA) and hepatic protein expression (normalized to GAPDH) after surgery and treatment. Hepatic 
gene expression of  (B) Gli1 and (C) Hhip after surgery and treatment. (D) Cytosolic and nuclear protein 
21 
 
levels (normalized to β-tubulin and lamin B1, respectively) of GLI1 and Cyclin D. (E) 
Immunofluorescence for hepatic GLI1. Note that SP600125 treatment reduces nuclear staining in 
hepatocytes. (F) Cyclin D counts (see Supplementary Fig. 9 for stains). N=5/group, t-test, *P<0.05, 
**P<0.01, ***P<0.001 for ALPPS + DMSO vs ALPPS + SP6. 
 
Figure 5. Effects of JNK1 inhibition combined with recombinant IHH treatment on regeneration after 
ALPPS. (A) Body weight and liver weight (FLR/BW) after ALPPS+ SP6 with/without  rIHH versus 
corresponding vehicle controls and ALPPS or PVL alone. (B) Corresponding Ki67 and pH3 counts (see 
Supplementary Fig. 10 for stain). N=5/group, t-test, *P<0.05, **P<0.01, ***P<0.001 for ALPPS + SP6 
versus ALPPS + SP6 and recombinant Ihh. 
 
Figure 6. Effects of JNK1 inhibition combined with recombinant IHH treatment on hedgehog 
signaling after ALPPS. (A) Hepatic gene expression of Gli1 and Hhip after surgery and treatment. (B) 
Cytosolic and nuclear protein levels (normalized to β-tubulin and lamin B1, respectively) of GLI1 and 
Cyclin D. (C) Immunofluorescence for hepatic GLI1. Note the restoration of nuclear GLI1 expression 
in SP600125-treated liver through rIHH. (D) Cyclin D nuclear counts see Supplementary Figure 11 for 
stains) (E) Cytosolic and nuclear protein levels of pJNK1. N=5/group,  t-test, *P<0.05, **P<0.01, 
***P<0.001 for ALPPS + SP6 versus ALPPS + SP6 and rIHH. 
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Supplementary Materials & Methods 
 
Quantitative real-time PCR  
Total RNA was extracted from 50 mg of tissue using Trizol reagent following provided 
instructions (Invitrogen, Basel, Switzerland). RNA quality/quantity was spectrometrically assessed. 
qPCR was performed with two replicates/sample on cDNA (Thermo Script reverse transcription PCR 
System, Invitrogen) using an ABI Prism 7500 Sequence Detector system (PE Applied Biosystems 
Rotkreuz, Switzerland). Taqman gene expression assays from Applied Biosystems are listed in 
Supplementary Table 1. Results represent mean fold induction (2
-ΔCt
) ±SD relative to the 
normalization control 18S rRNA.
1
  
Histological Examination 
Archived liver sections (3 μm) were stained (antibodies in Supplementary Table 2) using the 
Dako Autostainer Link48 Instrument and the iView DAB kit (Dako Denmark A/S). Quantification of 
Ki67-, bold pH3-, 
1
 cyclin D-, and pJNK-positive hepatocytes was achieved by blinded manual 
counting in 10 random visual fields (20x). For immunofluorescence, GLI1 antibody (R&D, Zug, 
Switzerland) was detected using an Alexa Fluor 488-conjugated anti-rat secondary antibody 
(Invitrogen, Zug, Switzerland). For co-immunofluorescence, primary antibodies are listed in 
Supplementary Table 2 and rabbit- and mouse-specific Alexa Fluor 488 and 594-conjugated secondary 
antibodies were used respectively. Representative slides of five biological samples per group are 
shown. 
  
  
Supplementary Tables 
 
Table S1. Taqman gene expression assays 
gene name Applied Biosystems order no.  
Gli1 Mm00494654_m1 
Gli2 Mm01293117_m1 
Hhip Mm00469580_m1 
Mapk8 Mm00489514_m1 
Mapk9 Mm_00444231_m1 
Mapk10 Mm_00436518_m1 
Ptch1 Mm00436026_m1 
Smo Mm01162710_m1 
18S rRNA  Control reagents 
 
Table S2. Antibodies 
Antigene Company (order no.) Dilution 
Ki67 Abcam, Cambridge, UK (ab16667) 1:200 (IHC) 
pH3 Millipore, Schaffhausen, CH (06-570) 1:500 (IHC) 
Gli1 R&D, Zug, CH (Mab3324) 
1:50 (IF) 
1:5000 (WB) 
Gli2 Abcam, Cambridge, UK (ab26056)  1:500 (WB) 
cyclin D Abcam, Cambridge, UK (ab16663) 
1:100 (IHC) 
1:100 (WB) 
Alpha-SMA Abcam, Cambridge, UK (ab32575) (IF) 
pJNK Santa Cruz, CA USA (sc6254) 1:50 (IF) 
pJNK R&D, Zug, CH (AF1205) (IHC) 
Ihh Abcam, Cambridge, UK (ab39634) 
1:250 (IF) 
1:500 (IHC) 
lamin B1 Santa Cruz, CA USA (sc-377001) 1:500 (WB) 
-tubulin Cell Signaling, MA USA (2128S) 1:1000 (WB) 
 
 
 
  
  
Supplementary Figures 
 
Figure S1. Serum injury levels and Mapk9/10 expression after ALPPS and control surgeries.  
 
Supplementary Figure 1. Upper graphs: serum ALT, AST and LDH levels after surgeries suggest similar injury 
levels after ALPPS and PVL surgery. Lower graphs: Gene expression for the JNK family members JNK2 and 
JNK3 (Mapk9, Mapk10) as assessed by qPCR.  
  
Figure S2. Immunohistochemistry for IHH, ASMA, and pJNK1 on liver post surgery. 
 
Supplementary Figure 2. Representative immunostainings for IHH, ASMA, and pJNK1 on liver at four hours 
after ALPPS, PVL, transection, and sham operations. Below images show pJNK1 at different times following 
PVL or ALPPS surgery. Arrows point to non-parenchymal cells with pJNK1 expression. Note that the 
immunohistochemical assessment of pJNK1 has to be interpreted with caution, as it did not reflect cytoplasmic 
expression detected by immunoblots. 40x magnification.   
  
Sham PVL 
pJNK 
ASMA 
DAPI 
merged 
Transection 
Figure S3. Immunofluorescent co-stains for pJNK1/ASMA and pJNK1/IHH on liver post 
control surgeries.       
 
 
 
 
 
 
 
Supplementary Figure 3. Representative 
immunofluorescent co-stains for pJNK1 
and ASMA, and pJNK and IHH on liver 
four hours after PVL, transection, and sham 
operations. 40x magnification. 
pJNK 
IHH 
DAPI 
merged 
  
 Figure S4. Immunofluorescent co-stains for pJNK1 and IHH on liver post PVL and ALPPS.  
Supplementary Figure 4. Representative immunofluorescent co-stains for pJNK/IHH on liver at 1, 4, and 
24 hours after ALPPS or PVL surgery. 40x magnification. 
 
  
      
Figure S5. JNK1 and GLI2 protein expression in ALPPS versus control surgeries.  
 
 
Supplementary Figure 5. JNK1 and GLI2 cytosolic and nuclear protein levels after ALPPS or its surgical 
controls. N=5 per group. t-test, *P<0.05, **P<0.01. ***P<0.001. Significances refer to ALPPS vs. PVL 
comparison unless otherwise stated.  
  
  
Figure S6. H&E staining and immunohistochemistry for Ki67, pH3, and cyclin D on liver 
post surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6. Representative immunostainings for H&E, Ki67, pH3, and cyclin 1 on liver after 
ALPPS, PVL, transection, and sham operations. For pH3, only cells with bold nuclear staining were counted, as 
these represent mitotic cells.
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 Quantitations are shown in Figure 1E. 20x magnification. 
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Figure S7. JNK1 nuclear and cytosolic protein levels after JNK inhibition with SP600125.  
 
Supplementary Figure 7. JNK1 nuclear and cytosolic protein levels determined by western blot in ALPPS 
livers with control injection (DMSO) or SP600125. N=5 per group. No significant differences between 
ALPPS+DMSO and ALPPS+SP6 group comparisons. 
  
  
Figure S8. Immunohistochemistry for H&E, Ki67, and pH3 on liver after JNK1 inhibition by 
SP6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8. Representative immunostainings for H&E, KI67, and pH3 on liver after treatment of 
ALPPS mice with DMSO, vehicle, or SP600125. 20x magnification. 
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Figure S9. mRNA analysis of Smo, Ptch1, Gli2, and Hhip in livers with JNK1 inhibition by 
SP6. 
 
 
 
 
  
Supplementary Figure 9. mRNA expression analysis of downstream components of IHH signaling in livers with 
JNK1 inhibition. N=5 per group. No significant differences between ALPPS+DMSO and ALPPS+SP6 group 
comparison.  
  
Figure S10. GLI2 protein levels in livers with JNK1 inhibition by SP6.  
 
 
Supplementary Figure 10. Hepatic GLI2 protein levels in nuclear and cytosolic fractions after vehicle (DMSO) 
or SP600125 treatment followed by ALPPS. N=5 per group. No significant differences between ALPPS+DMSO 
and ALPPS+SP6 group comparison.  
 
  
  
Figure S11. Immunohistochemistry for cyclin D1 on liver after JNK1 inhibition by SP6. 
 
Supplementary Figure 11. Representative immunostainings for pJNK and cyclin D on liver after treatment of 
ALPPS mice with DMSO vehicle or SP600125. 20x magnification.  
  
  
Figure S12. Immunohistochemistry for H&E, Ki67, and pH3 on livers with JNK1 inhibition 
by SP6 and recombinant IHH treatment.  
 
Supplementary Figure 12. Representative immunostainings for H&E, KI67, and pH3 on liver after treatment of 
ALPPS mice with vehicle injections (DMSO and PBS), or SP600125, or SP600124 and recombinant IHH 
injections. 20x magnification. 
  
  
Figure S13. Immunohistochemistry for cyclin D on liver after JNK1 inhibition and 
recombinant IHH treatment. 
 
 
Supplementary Figure 13. Representative immunostainings for pJNK and cyclin D1 on liver after treatment of 
ALPPS mice with vehicle (DMSO and PBS), or SP600125, or SP600125 and recombinant IHH treatment. 20x 
magnification. 
 
 
 
  
  
Figure S14. mRNA analysis of Ptch1, Smo, Gli2, and Hhip in livers with JNK1 inhibition 
and recombinant IHH treatment.  
 
 
  
Supplementary Figure 14. mRNA expression analysis of downstream components of IHH signaling in livers 
with JNK inhibition and recombinant IHH treatment. N=5 per group. t-test, *P < 0.05, **P < 0.01. ***P < 
0.001. Significances refer to ALPPS+SP6 vs. ALPPS+SP6+rIHH comparison. Note that the significant 
changes in Smo expression were not further analyzed, as Smo gene expression correlated neither with 
regenerative responses nor with GLI1 activation.  
 
  
Figure S15. GLI2 protein levels in livers with JNK1 inhibition and recombinant IHH 
treatment.  
 
 
Supplementary Figure 15. GLI2 protein levels in nuclear and cytosolic fractions in livers with vehicle 
(DMSO&PBS), or SP600125, or SP600125 and recombinant IHH treatment. The significant downregulation of 
nuclear GLI2 through IHH treatment further corroborates that GLI2 does not contribute to the JNK1-IHH axis in 
ALPPS. N=5 per group. t-test, *P < 0.05, **P < 0.01. ***P < 0.001. Significances refer to ALPPS+SP6 vs. 
ALPPS+SP6+rIHH comparison.  
  
  
Figure S16. JNK1 protein levels in livers after JNK loss treatment and recombinant Ihh 
treatment.  
 
 
Supplementary Figure 16. JNK1 protein levels in nuclear and cytosolic fractions in livers of ALPPS mice 
treated with vehicle injection (DMSO & PBS), or SP600125, or SP600125 and recombinant IHH (referring to 
Figure 6E). N=5 per group. t-test, *P < 0.05, **P < 0.01. ***P < 0.001. Significances refer to ALPPS+SP6 vs. 
ALPPS+SP6+rIHH comparison.   
  
  
Figure S17. Immunohistochemistry for pJNK1 on liver after JNK1 inhibition and 
recombinant IHH treatment. 
 
 
Supplementary Figure 17. Representative immunostainings for pJNK1 on liver after treatment of ALPPS mice 
with vehicle (DMSO and PBS), or SP600125, or SP600125 and recombinant IHH treatment. 20x magnification.  
 
  
  
Figure S18. Immunofluorescence for pJNK1 and IHH on liver after PVL and PBS injection 
or rIHH injection.  
 
Supplementary Figure 18. Representative immunostainings for pJNK1 and IHH at 4h and 12h after PVL 
surgery with concomitant injection of PBS (control) or rIHH. We have previously shown that rIHH treatment of 
PVL mice induces GLI1-cyclin D1, promotes hepatocellular proliferation, and accelerates regeneration to levels 
observed in ALPPS mice, demonstrating the central role of IHH in ALPPS.
2
 Relative to controls, rIHH also 
elevated pJNK expression in stellate cells, provding further evidence for a positive feedback loop between IHH 
and JNK1.  
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